Allergan obtains rights to microbiome GI developmental program: 3 key notes
Dublin, Ireland-based Allergan entered into a research, development, collaboration and license agreement to develop Indianapolis's Assembly Biosciences microbiome gastrointestinal development programs.
Here's what you need to know.
1. Allergan received the rights to preclinical compounds ABI-M201 and ABI-M301 targeting ulcerative colitis and Crohn's disease. Allergan also received rights to two compounds targeting various forms of irritable bowel syndrome.
2. Allergan will pay $50 million to Assembly. Assembly will also hold various different types of royalties.
3. The transaction should close in the first quarter of 2017.
More articles on gastroenterology/endoscopy:
GI leader to know: Dr. Bitman Stewart of Digestive Care
Integrated Endoscopy seeks $4.4M for executive compensation: 3 key notes
Hallmark Health Medical Associates names gastroenterologist Dr. Michael Newman president: 3 key notes
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- Participants race to increase colon cancer awareness during 2017 Greater Chattanooga Rump Run 5K and Fun Walk: 4 takeaways
- US woman dies from superbug resistant to 26 antibiotics — 8 things to know
- Healthcare nanotechnology market to grow at a CAGR above 12% till 2024
- American Anesthesiology to exhibit at ASA's Practice Management 2017: 3 things to know
- Gastroenteropancreatic neuroendocrine tumor patients utilize combination therapy: 5 study insights